Daily Bio News Summary — 2026-08-15: FDA nods, merger activity, and hepatitis milestones

Today’s harvest

Nine articles from five sources made it through the 30-day freshness filter, the political filter (13 items dropped — mostly vaccine-policy opinion and one op-ed), and the Endpoints paywall gate (7 articles behind Endpoints Pro). What remains is a clean batch of product-level news and deal activity, with zero editorial or politically charged content.

---

FDA and regulatory activity

Bristol Myers Squibb’s Zenbexus wins first-in-class FDA nod in multiple myeloma (MedCity News, 2026-08-01). Bristol Myers Squibb has received FDA approval for Zenbexus, the first drug in a new class of targeted protein degraders called CELMoDs. The approval positions Zenbexus as a successor to the company’s legacy multiple myeloma portfolio.

Capricor seeks FDA review extension for Duchenne cell therapy (BioSpace, 2026-08-14). Capricor Therapeutics is in active discussions with the FDA ahead of its August 22 deadline, seeking an extension to file amendments to its approval application for deramiocel, a cell therapy for Duchenne muscular dystrophy.

Tavneos trial flagged for ‘serious breaches’ by EU regulators (Fierce Pharma, 2026-08-14). EU regulators have published a post-mortem of their decision to revoke the marketing authorization for Tavneos, a rare-disease medication, citing “serious breaches of protocol” in the pivotal trial.

---

Deal activity and M&A

Skye Bioscience and Redx Pharma combine into Fibrx Therapeutics with $125M in financing (Fierce Biotech, 2026-08-14). Skye Bioscience (NASDAQ: SKYE) and UK-based Redx Pharma have merged to create Fibrx Therapeutics, a new public company focused on fibrosis. The deal nets $150 million in financing for the combined entity.

Lilly, PTC snap up Sangamo’s key assets from bankruptcy (Pharmaphorum, 2026-08-15). Just weeks after filing for bankruptcy protection, Sangamo Therapeutics has found buyers for its main assets, raising up to $85 million. Eli Lilly and PTC Therapeutics are the acquirers.

BMS faces revived Celgene investor lawsuit (Fierce Pharma, 2026-08-14). A U.S. appeals court has revived a lawsuit by Celgene investors accusing Bristol-Myers Squibb of intentionally slowing the approval of Breyanzi to avoid triggering a large contingent value right (CVR) payout.

---

Clinical readouts

Definium reports positive Phase 3 data for LSD-based therapy DT120 (Pharmaphorum, 2026-08-15). Psychedelic drug developer Definium Therapeutics has posted a Phase 3 win with its LSD-based therapy DT120, advancing the case for psychedelic-assisted therapy in treatment-resistant depression.

---

Public health and technology

England close to eliminating hepatitis C (Pharmaphorum, 2026-08-15). England is on track to become one of the first countries in the world to eliminate hepatitis C, driven by a national diagnosis and treatment program.

Novo Nordisk partners Amazon on London AI hub (Pharmaphorum, 2026-08-15). Novo Nordisk has partnered with Amazon Web Services to create an AI co-innovation hub in London, signaling the growing integration of cloud AI infrastructure into pharmaceutical R&D.

---

What this batch is not telling us

Today’s harvest has no items on:

• IPOs or public offerings — the market continues to be quiet on the biotech IPO front.
• AI-native drug discovery — despite the Novo Nordisk–AWS partnership, there are no new clinical-stage AI-bio stories this cycle.
• Vaccine policy or FDA leadership politics — these were present in the raw harvest but filtered out per the project’s editorial standards.

---

Reading order

For readers with limited time, start with:

1. Skye–Redx merger (Fierce Biotech) — the largest financing event of the day and a signal that fibrosis is getting renewed capital attention.
2. Definium Phase 3 win (Pharmaphorum) — a milestone for psychedelic therapeutics and the broader category of LSD-based treatments.
3. BMS Zenbexus approval (MedCity News) — first-in-class approvals define the therapeutic landscape for years to come.
4. Capricor FDA extension (BioSpace) — a critical regulatory inflection point for Duchenne families.

---

Today’s news files

All source URLs are available in src/content/news/ via the sourceUrl frontmatter field. Today’s files:

1. Novo Nordisk partners Amazon on London AI hub — Pharmaphorum
2. England close to eliminating hep C — Pharmaphorum
3. Lilly, PTC snap up bankrupt Sangamo’s main assets — Pharmaphorum
4. Definium chalks up new phase 3 win for LSD-based therapy — Pharmaphorum
5. BMS vs. Celgene investors — appeals court revives lawsuit — Fierce Pharma
6. Tavneos trial flagged for protocol breaches — EU regulators — Fierce Pharma
7. Skye and Redx form Fibrx Therapeutics with $125M — Fierce Biotech
8. Capricor seeks FDA review extension — BioSpace
9. BMS CELMoD Zenbexus wins first-in-class FDA nod — MedCity News